Cargando…

P501: ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS

Detalles Bibliográficos
Autores principales:	Baruchel, André, Bertrand, Yves, Nysom, Karsten, Jin Kang, Hyoung, Makiya, Monica, Abrahamsson, Jonas, González-Llano, Oscar, Quinones Choque, Willy, Rizzari, Carmelo, Buechner, Jochen, Cesaro, Simone, Duarte, Ximo, Fagioli, Franca, Kattamis, Antonis, Leverger, Guy, Nelken, Brigitte, Wang, Lynn, Mace, Sandrine, Oprea, Corina, Abbadessa, Giovanni, Zwaan, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429338/ http://dx.doi.org/10.1097/01.HS9.0000968912.12181.3e

Ejemplares similares

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study
por: Boissel, Nicolas, et al.
Publicado: (2022)

Road Traffic and Childhood Leukemia: The ESCALE Study (SFCE)
por: Amigou, Alicia, et al.
Publicado: (2011)

Infant Acute Myeloid Leukemia: A Unique Clinical and Biological Entity
por: Calvo, Charlotte, et al.
Publicado: (2021)

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
por: Martin, Thomas G., et al.
Publicado: (2019)

Is Acute Myeloblastic Leukemia in Children Under 2 Years of Age a Specific Entity? A Report from the FRENCH ELAM02 Study Group
por: Blais, S., et al.
Publicado: (2019)

Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg(®)) in children with relapsed/refractory myeloid leukemia
por: Brethon, Benoit, et al.
Publicado: (2006)

COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE)
por: Baruchel, André, et al.
Publicado: (2020)

COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE)
por: Rouger-Gaudichon, Jérémie, et al.
Publicado: (2021)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
por: Millot, Frédéric, et al.
Publicado: (2021)

Isatuximab: A Review of Its Use in Multiple Myeloma
por: Frampton, James E.
Publicado: (2021)

A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
por: Carlo‐Stella, Carmelo, et al.
Publicado: (2022)

Correction to: Isatuximab: A Review of Its Use in Multiple Myeloma
por: Frampton, James E.
Publicado: (2021)

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
por: Shen, Fei, et al.
Publicado: (2022)

Day-care, early common infections and childhood acute leukaemia: a multicentre French case–control study
por: Perrillat, F, et al.
Publicado: (2002)

Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase Erwinia chrysanthemi
por: Tong, Wing H., et al.
Publicado: (2023)

A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia
por: Kobayashi, Yukio, et al.
Publicado: (2017)

Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia
por: Vercueil, Colin, et al.
Publicado: (2021)

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2019)

Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma
por: Idogun, Precious O, et al.
Publicado: (2022)

Preparing for R501
Publicado: (1977)

ARID5B, IKZF1 and Non-Genetic Factors in the Etiology of Childhood Acute Lymphoblastic Leukemia: The ESCALE Study
por: Rudant, Jérémie, et al.
Publicado: (2015)

Año 501 : la conquista continúa /
por: Chomsky, Noam
Publicado: (1993)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
por: Hulin, Cyrille, et al.
Publicado: (2021)

Listeria monocytogenes Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma
por: Ueno, Toshiyuki, et al.
Publicado: (2021)

Late effects in survivors of infantile acute leukemia: a study of the L.E.A program
por: Gandemer, V, et al.
Publicado: (2017)

Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia
por: Poglio, Sandrine, et al.
Publicado: (2016)

Leukemia Cutis in Childhood Acute Myeloid Leukemia: Epidemiological, Clinical, Biological, and Prognostic Characteristics of Patients Included in the ELAM02 Study
por: Gouache, Elodie, et al.
Publicado: (2018)

Oxidative Stress and ROS-Mediated Signaling in Leukemia: Novel Promising Perspectives to Eradicate Chemoresistant Cells in Myeloid Leukemia
por: Trombetti, Silvia, et al.
Publicado: (2021)

Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group
por: Lew-Derivry, Lucille, et al.
Publicado: (2023)

Dictionary of 501 Spanish Verbs
por: Kendris, C.
Publicado: (1971)

Clipper 5.01 avanzado /
por: Ramalho, José A.
Publicado: (1992)

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
por: Simonelli, M., et al.
Publicado: (2022)

CompTIA Security+ SY0-501 review guide: exam SY0-501
por: Stewart, James M
Publicado: (2018)

Scientific Opinion on Flavouring Group Evaluation 501 (FGE.501): Grill flavour concentrate (vegetable)
por: Younes, Maged, et al.
Publicado: (2019)

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2022)

Prognosis Factors in Chronic Lymphocytic Leukemia
por: Ivanescu, AM, et al.
Publicado: (2012)

BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy
por: Cario, Gunnar, et al.
Publicado: (2020)

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
por: Mikhael, Joseph, et al.
Publicado: (2020)

Household Exposure to Pesticides and Risk of Childhood Hematopoietic Malignancies: The ESCALE Study (SFCE)
por: Rudant, Jérémie, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_4dmes1qiqkiao0c2aaam0e015n